CAPTAIN STUDY: ASSOCIATION OF MODERATE AND SEVERE ASTHMA EXACERBATIONS WITH LUNG FUNCTION AND PATIENT-REPORTED OUTCOMES IN A LARGE RANDOMIZED PHASE III CLINICAL TRIAL

被引：0
|
作者：
Sule, Neal
Fowler, Andrew
Kerstjens, Huib
Kerwin, Edward
Lee, Laurie
Nathan, Robert
Oppenheimer, John
Pavord, Ian
Peachey, Guy
Tabberer, Maggie
Zarankaite, Agne
Manning, Michael
Millard, Mark
Mannino, David
Hanania, Nicola
机构：
来源：
CHEST | 2020年 / 158卷 / 04期
关键词：
D O I：
10.1016/j.chest.2020.08.072
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：35A / 38A
页数：4
相关论文
共 50 条
  • [1] Impact of adalimumab treatment on patient-reported outcomes: Results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis
    Revicki, Dennis A.
    Willian, Mary Kaye
    Menter, Alan
    Gordon, Kenneth B.
    Kimball, Alexa B.
    Leonardi, Craig L.
    Langley, Richard G.
    Kimel, Miriam
    Okun, Martin
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2007, 18 (06) : 341 - 350
  • [2] Patient-reported outcomes with abrocitinib treatment in patients with moderate to severe atopic dermatitis: Results from a randomized, phase 3 clinical trial
    Silverberg, Jonathan I.
    Cohen, Arnon D.
    Stander, Sonja
    Feeney, Claire
    Valdez, Hernan
    Biswas, Pinaki
    Cameron, Michael C.
    DiBonaventura, Marco
    Gerber, Robert A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB35 - AB35
  • [3] Clinical Efficacy of Omalizumab, as Measured by Patient-Reported Outcomes, in Chinese Patients with Moderate or Severe Allergic Asthma
    Wang, C.
    Li, J.
    Kang, J.
    Yang, J.
    Lin, Z.
    Wang, S.
    Humphries, M.
    Kottakis, I.
    Fogel, R.
    Zhong, N.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [4] Patient-reported Outcomes and Clinical Response in Patients with Moderate-to-severe Plaque Psoriasis Treated with Tonsillectomy: A Randomized Controlled Trial
    Thorleifsdottir, Ragna Hlin
    Sigurdardottir, Sigrun Laufey
    Sigurgeirsson, Bardur
    Olafsson, Jon Hjaltalin
    Sigurdsson, Martin Ingi
    Petersen, Hannes
    Gudjonsson, Johann Eli
    Johnston, Andrew
    Valdimarsson, Helgi
    ACTA DERMATO-VENEREOLOGICA, 2017, 97 (03) : 340 - 345
  • [5] Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial
    Krueger, GG
    Langley, RG
    Finlay, AY
    Griffiths, CEM
    Woolley, JM
    Lalla, D
    Jahreis, A
    BRITISH JOURNAL OF DERMATOLOGY, 2005, 153 (06) : 1192 - 1199
  • [6] Incorporating patient-reported outcomes in a phase I clinical trial
    Qin, Rui
    Dueck, Amylou C.
    Satele, Daniel
    Molina, Julian
    Erlichman, Charles
    Basch, Ethan
    Sloan, Jeff
    QUALITY OF LIFE RESEARCH, 2013, 22
  • [7] Muscle function in moderate to severe asthma: association with functional and clinical outcomes
    Visser, Edith
    De Jong, Kim
    Van Zutphen, Tim
    Kerstjens, Huib A. M.
    Ten Brinke, Anneke
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [8] Risankizumab significantly improves patient-reported outcomes in moderate to severe psoriasis in two phase III UltIMMa trials
    Augustin, M.
    Lambert, J.
    Zema, C.
    Thompson, E. H.
    Yang, M.
    Wu, E.
    Geng, Z.
    Valdes, J.
    Skup, M.
    Gordon, K.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 118 - 118
  • [9] Impact of efalizumab on patient-reported outcomes in patients with moderate to severe plaque psoriasis: Pooled results from three randomized phase III trials
    Menter, A
    Hamilton, T
    Caro, I
    Chen-Rundle, A
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) : P156 - P156
  • [10] Patient-reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate-to-severe atopic dermatitis
    Thyssen, J. P.
    Yosipovitch, G.
    Paul, C.
    Kwatra, S. G.
    Chu, C. Y.
    DiBonaventura, M.
    Feeney, C.
    Zhang, F.
    Myers, D.
    Rojo, R.
    Valdez, H.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (03) : 434 - 443
12345